WASHINGTON – International will be front and center at this year's BIO International Convention taking place this week in Washington – both in who's coming and in what's being discussed.
WASHINGTON – When it comes to patent reform, the cure may not treat the bite of a growing backlog of patent applications – about 700,000 at last count.
With its sights set on pushing two cancer candidates through the pipeline, GTx Inc. is looking to a $47.5 million public offering to fund Phase III development of Ostarine and Phase II trials for Capesaris.
Regeneron Pharmaceuticals Inc. sold an FDA advisory committee on the benefits of its Eylea as an every-other-month treatment for the neovascular form of age-related macular degeneration (wet AMD).
WASHINGTON – The battle lines have been drawn over how big of an increase the FDA needs in fiscal 2012. House Republicans have said 11 percent should do it, but the president wants a lot more.
WASHINGTON – While Congress may be on the verge of passing the first major patent reform in nearly 60 years, the courts have been steadily shaping and redefining the nation's patent system in a series of recent decisions that may be "game changers" for biotech.
When it comes to getting an injection in the eye, the fewer the better. That's what Regeneron Pharmaceuticals Inc. is counting on to drive its Eylea into the market for the neovascular form of age-related macular degeneration (wet AMD).
WASHINGTON – When it comes to nanotechnology, size does matter, the FDA said in a new draft guidance, which is more of a conversation starter than an actual guidance.
